Smart’ Wound-Care Technology Reduces Costs By More Than 30%
Study finds self-adapting dressing significantly reduces cost of care while providing better clinical outcomes and simplifying wound-care procedures.
SANTA CLARA, Calif. — July 18, 2014 — The “Any Wound” Enluxtra dressing developed and distributed by OSNovative Systems, Inc., can reduce healthcare spending on primary wound dressings by upwards of 30 percent, according to a new study.
The study, conducted at the Southwest Regional Wound Care Center in Lubbock, Texas, quantified cost savings from 70 percent reduction in primary wound-dressing inventory made possible by Enluxtra’s self-adaptive technology, which adjusts to the healing needs of any wound, in any stage of healing.
Standardization to the moderately priced Self-Adaptive Wound Dressing (SAWD) replaced dozens of products including primary foam; alginate; hydro- and hydro-conductive fiber; super-absorbent collagen; hydrocolloid; hydrogel; gauze; and combination dressings including silver-containing products wound contact non-adhering layers, skin preps and moisture barriers.
Additional savings noted in the study came from the simplification of wound care protocol, training, documentation and inventory management.
In the U.S. alone, around 6.5 million patients1 are treated for chronic wounds at an estimated annual cost of $25 billion2. These figures are expected to rise with the aging population and the spread of chronic conditions like cardiovascular problems, obesity and diabetes.
In addition to reducing costs for clinics, hospitals, long-term care facilities, hospice and home care, Enluxtra also promises to improve patient care. While in contact with a wound, Enluxtra’s proprietary FDA-approved polymers sense and accommodate the different parts of the wound that need hydration or absorption. A single Enluxtra dressing continually adapts its function for up to seven days, maintaining the optimum moisture balance for healing and preventing wound maceration and desiccation.
In the study, the Enluxtra SAWD was used with 547 patients suffering from 1,168 chronic and acute wounds. Based on questionnaire responses, average patient and caregiver satisfaction were higher with SAWD compared to prior dressings, due to “consistently faster wound improvements, decreased dressing change frequency, reduced pain and odor, painless dressing changes, superior drainage management, and prevention of skin maceration.”
Since the release of Enluxtra in 2012, more than 20,000 patients across the U.S. have been treated with the advanced dressing, and clinical and anecdotal evidence further demonstrate the benefits noted in the study.
The combination of patient outcomes and cost benefits led to OSNovative’s receipt of the 2014 North American Frost & Sullivan Award for New Product Innovation Leadership. “The use of Enluxtra translates into significant cost-savings and successful treatment outcomes,” said Frost & Sullivan Research Analyst Geethu Roshan Verghese. “By addressing the needs of healthcare professionals and patients alike, Enluxtra has effectively bridged vital gaps in the wound-care industry.”
Medical professionals can request free samples of Enluxtra at www.AnyWound.com. Orders can be placed through nationwide distributors or directly with OSNovative Systems. Consumers have the option to purchase Enluxtra online or fill a prescription via select providers.
About OSNovative Systems Inc.
OSNovative Systems, Inc. is a pioneer in self-adaptive wound care technology committed to developing, manufacturing and selling proprietary devices for advanced wound management, combat/emergency medicine and cosmetic skin care. This Silicon Valley-based start-up is owned and managed by a team of dedicated professionals, who are passionate about bringing the most innovative wound care products to healthcare providers and patients.
For more information about self-adaptive technology, testimonies and clinical studies, please visit: www.AnyWound.com.
Sources:
1. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med 1999;341:738–46. [PubMed: 10471461]
2. Brem H, Stojadinovic O, Diegelmann RF, Entero H, Lee B, Pastar I, Golinko M, Rosenberg H, Tomic- Canic M. Molecular markers in patients with chronic wounds to guide surgical debridement. Mol Med 2007;13:30–9. [PubMed: 17515955]
